Semaglutide showed CV benefits in PIONEER-6 and SUSTAIN-6, which are consistent with other CVOTs studying GLP-1 RAs, such as EXSCEL, HARMONY, LEADER, REWIND and ELIXA, which included patients on exenatide, albiglutide, liraglutide, dulaglutide and lixisenatide, respectively [41, 42]
GLP-1 agonists may affect the interpretation of oncological FDG PET-CT scans owenhaskins Oct 7, 2025 2 min read The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, according to research presented at the 38th Annual Congress of the European Association of Nuclear Medicine (EANM'25)
duration data for GI side effects
Actavis (2013), holding instead that courts must apply a rule of reason analysis to reverse payment settlements [25]
Both classes of drugs prevent kidney disease progression and lower the risk of common cardiovascular complications